Two Y-90-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy
文献类型：期刊论文
| 作者 | Liu, Zhaofei1,2; Shi, Jiyun1,2; Jia, Bing1,2; Yu, Zilin1,2; Liu, Yan1,2; Zhao, Huiyun1,2; Li, Fang3; Tian, Jie4 ; Chen, Xiaoyuan5; Liu, Shuang6
|
| 刊名 | MOLECULAR PHARMACEUTICS
 |
| 出版日期 | 2011-03-01 |
| 卷号 | 8期号:2页码:591-599 |
| 关键词 | integrin alpha(v)beta(3) Arg-Gly-Asp (RGD) Y-90 tumor radionuclide therapy |
| 英文摘要 | We have recently developed a series of new Arg-Gly-Asp (RGD) dimeric peptides for specific targeting of integrin alpha(v)beta(3) with enhanced tumor uptake and improved pharmacokinetics. In this study, we investigated Y-90-labeled RGD tetramer (RGD4) and the new type of RGD dimer (3PRGD2), for the radionuclide therapy of integrin alpha(v)beta(3)-positive tumors. Biodistribution and gamma imaging studies of In-111 labeled RGD4 and 3PRGD2 were performed. Groups of nude mice were used to determine maximum tolerated dose (MTD) of Y-90-DOTA-RGD4 and Y-90-DOTA-3PRGD2. The radionuclide therapeutic efficacy of Y-90-DOTA-RGD4 and 90Y-DOTA-3PRGD2 was evaluated in U87MG tumor-bearing nude mice. The U87MG tumor uptake of In-111-DOTA-3PRGD2 was slightly lower than that of the In-111-DOTA-RGD4 (e.g., 6.13 +/- 0.82%ID/g vs 6.43 +/- 1.6%ID/g at 4 h post-injection), but the uptake of In-111-DOTA-3PRGD2 in normal organs, such as liver and kidneys, was much lower than that of In-111-DOTA-RGD4, which resulted in much higher tumor-to-nontumor ratios and lower toxicity. The MTD of Y-90-DOTA-RGD4 in nude mice is less than 44.4 MBq, while the MTD of Y-90-DOTA-3PRGD2 in mice is more than 55.5 MBq. Y-90-DOTA-3PRGD2 administration exhibited a similar tumor inhibition effect as compared with Y-90-DOTA-RGD4 at the same dose. The tumor vasculature in the Y-90-DOTA-3PRGD2 treatment group was much less than the control groups. Radionuclide therapy studies exhibited that both Y-90-DOTA-RGD4 and Y-90-DOTA-3PRGD2 caused significant tumor growth delay in the U87MG tumor model. Compared to Y-90-DOTA-RGD4, the low accumulation of Y-90-DOTA-3PRGD2 in normal organs led to lower toxicity and higher MTD in nude mice, which would make it more suitable for high dose or multiple-dose regimens, in order to achieve maximum therapeutic efficacy. |
| WOS标题词 | Science & Technology ; Life Sciences & Biomedicine |
| 类目[WOS] | Medicine, Research & Experimental ; Pharmacology & Pharmacy |
| 研究领域[WOS] | Research & Experimental Medicine ; Pharmacology & Pharmacy |
| 关键词[WOS] | POSITRON-EMISSION-TOMOGRAPHY ; IMPROVING TUMOR UPTAKE ; SMALL-ANIMAL PET ; ALPHA(V)BETA(3) INTEGRIN ; CANCER-PATIENTS ; PEG(4) LINKERS ; ANGIOGENESIS ; EXPRESSION ; DIMERS ; PHARMACOKINETICS |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000289008600028 |
| 公开日期 | 2015-12-24 |
| 源URL | [http://ir.ia.ac.cn/handle/173211/9758]  |
| 专题 | 自动化研究所_中国科学院分子影像重点实验室 |
| 作者单位 | 1.Peking Univ, Med Isotopes Res Ctr, Beijing 100191, Peoples R China 2.Peking Univ, Dept Radiat Med, Beijing 100191, Peoples R China 3.Beijing Union Med Coll Hosp, Dept Nucl Med, Beijing 100857, Peoples R China 4.Chinese Acad Sci, Med Image Proc Grp, Inst Automat, Beijing 100190, Peoples R China 5.Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA 6.Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA |
| 推荐引用方式 GB/T 7714 | Liu, Zhaofei,Shi, Jiyun,Jia, Bing,et al. Two Y-90-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy[J]. MOLECULAR PHARMACEUTICS,2011,8(2):591-599. |
| APA | Liu, Zhaofei.,Shi, Jiyun.,Jia, Bing.,Yu, Zilin.,Liu, Yan.,...&Wang, Fan.(2011).Two Y-90-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy.MOLECULAR PHARMACEUTICS,8(2),591-599. |
| MLA | Liu, Zhaofei,et al."Two Y-90-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy".MOLECULAR PHARMACEUTICS 8.2(2011):591-599. |
入库方式： OAI收割
来源：自动化研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。